ATE469908T1 - Verfahren zur herstellung von pimecrolimus - Google Patents

Verfahren zur herstellung von pimecrolimus

Info

Publication number: ATE469908T1
Authority: AT; Austria
Prior art keywords: pimecrolimus; producing; macrolides; tacrolimus; crystallization
Prior art date: 2004-12-01

Application number

AT05848723T

Other languages

English (en)

Inventor

Viktor Gyollai

Csaba Szabo

Original Assignee

Teva Gyogyszergyar Zartkoeruen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-01

Filing date

2005-12-01

Publication date

2010-06-15

2005-12-01 Application filed by Teva Gyogyszergyar Zartkoeruen filed Critical Teva Gyogyszergyar Zartkoeruen

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE469908T1 publication Critical patent/ATE469908T1/de

Links

KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 title abstract 2
229960005330 pimecrolimus Drugs 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
238000002425 crystallisation Methods 0.000 abstract 1
230000008025 crystallization Effects 0.000 abstract 1
239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
229940041033 macrolides Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960001967 tacrolimus Drugs 0.000 abstract 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT05848723T 2004-12-01 2005-12-01 Verfahren zur herstellung von pimecrolimus ATE469908T1 (de)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US63237204P	2004-12-01	2004-12-01
US63392604P	2004-12-06	2004-12-06
US64186805P	2005-01-05	2005-01-05
US64169705P	2005-01-05	2005-01-05
US64186905P	2005-01-05	2005-01-05
US66244005P	2005-03-16	2005-03-16
US70568105P	2005-08-03	2005-08-03
US70916005P	2005-08-17	2005-08-17
PCT/US2005/043541 WO2006060614A1 (en)	2004-12-01	2005-12-01	Methods for preparing pimecrolimus

Publications (1)

Publication Number	Publication Date
ATE469908T1 true ATE469908T1 (de)	2010-06-15

Family

ID=36097009

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05848723T ATE469908T1 (de)	2004-12-01	2005-12-01	Verfahren zur herstellung von pimecrolimus

Country Status (11)

Country	Link
US (5)	US7279571B2 (de)
EP (4)	EP1817317B1 (de)
JP (4)	JP2007519757A (de)
KR (1)	KR20070060144A (de)
AT (1)	ATE469908T1 (de)
CA (4)	CA2584430A1 (de)
DE (1)	DE602005021684D1 (de)
IL (4)	IL182871A0 (de)
MX (2)	MX2007005222A (de)
TW (3)	TW200628483A (de)
WO (4)	WO2006060615A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6306166B1 (en) *	1997-08-13	2001-10-23	Scimed Life Systems, Inc.	Loading and release of water-insoluble drugs
CA2560984A1 (en) *	2004-06-01	2005-12-15	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Process for preparation of amorphous form of a drug
CA2584430A1 (en) *	2004-12-01	2006-06-08	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Methods for preparing pimecrolimus
US7820812B2 (en)	2006-07-25	2010-10-26	Abbott Laboratories	Methods of manufacturing crystalline forms of rapamycin analogs
JP2010500286A (ja) *	2006-07-25	2010-01-07	アボット・ラボラトリーズ	結晶形態のラパマイシン類似体
US7812032B2 (en)	2006-07-25	2010-10-12	Abbott Laboratories	Crystalline forms of rapamycin analogs
TW200837067A (en) *	2006-11-06	2008-09-16	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
JP2010515753A (ja)	2007-01-10	2010-05-13	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	肺内送達用免疫抑制剤組成物の送達の増強
ES2393639T3 (es)	2007-01-21	2012-12-26	Hemoteq Ag	Producto médico para tratar cierres de conductos corporales y prevención de nuevos cierres
US7790887B2 (en) *	2007-01-29	2010-09-07	Eisai R&D Management Co., Ltd.	Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
US9192697B2 (en)	2007-07-03	2015-11-24	Hemoteq Ag	Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
CL2008000374A1 (es) *	2008-02-05	2008-04-04	Igloo Zone Chile S A	Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
CN102282457A (zh) *	2009-01-21	2011-12-14	拜康有限公司	确定西罗莫司稳定性的方法和制备其稳定形式的工艺
IT1394309B1 (it)	2009-05-22	2012-06-06	Poli Ind Chimica Spa	Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
EP2944332B1 (de)	2009-07-10	2016-08-17	Boston Scientific Scimed, Inc.	Verwendung von nanokristallen für einen wirkstofffreisetzungsballon
EP2453938B1 (de)	2009-07-17	2015-08-19	Boston Scientific Scimed, Inc.	Nukleierung von wirkstofffreisetzungsballons für verbesserte kristallgrösse und -dichte
US20110160645A1 (en) *	2009-12-31	2011-06-30	Boston Scientific Scimed, Inc.	Cryo Activated Drug Delivery and Cutting Balloons
WO2011122573A1 (ja) *	2010-03-29	2011-10-06	ダイキン工業株式会社	３－クロロ－ペンタフルオロプロペンの製造方法
US9878328B2 (en)	2010-07-23	2018-01-30	Curiox Biosystems Pte Ltd.	Apparatus and method for multiple reactions in small volumes
WO2012017449A1 (en)	2010-08-04	2012-02-09	Meril Life Sciences Pvt. Ltd	Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
EP2611476B1 (de)	2010-09-02	2016-08-10	Boston Scientific Scimed, Inc.	Beschichtungsverfahren für wirkstofffreisetzungsballons mit wärmeinduziertem rewrap-gedächtnis
US9327264B2 (en) *	2011-01-31	2016-05-03	Uchicago Argonne, Llc	Containerless synthesis of amorphous and nanophase organic materials
US8669360B2 (en)	2011-08-05	2014-03-11	Boston Scientific Scimed, Inc.	Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en)	2011-08-25	2013-02-28	Boston Scientific Scimed, Inc.	Medical device with crystalline drug coating
WO2014145780A1 (en)	2013-03-15	2014-09-18	Biosensors International Group, Ltd.	Purification of rapamycin derivatives
MY180626A (en)	2013-11-15	2020-12-03	Akebia Therapeutics Inc	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016078481A1 (zh)	2014-11-21	2016-05-26	杭州领业医药科技有限公司	一种含他克莫司的药物组合物及其制备方法
CA2998651C (en) *	2015-11-28	2021-01-19	Biopreme Medical Technologies Inc.	Negative pressure injection device
EP3178824A1 (de)	2015-12-08	2017-06-14	Medichem, S.A.	Verfahren zur herstellung von pimecrolimus
ES2906158T3 (es)	2017-05-01	2022-04-13	Meda Pharma Gmbh & Co Kg	Proceso para convertir ascomicina bruta en pimecrolimus purificado
CN108948046B (zh) *	2017-05-20	2020-11-10	鲁南制药集团股份有限公司	一种替西罗莫司的中间体及其制备方法
CN110540567B (zh) *	2018-05-28	2024-07-30	深圳市天维生物药业有限公司	一种天维菌素b的晶型及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3244592A (en) *	1962-06-09	1966-04-05	Arai Tadashi	Ascomycin and process for its production
US4894366A (en) *	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
WO1989000576A1 (en) *	1987-07-09	1989-01-26	Pfizer Inc.	Azithromycin dihydrate
EP0323865A1 (de) *	1988-01-07	1989-07-12	Merck & Co. Inc.	Immunopressantes Mittel
ATE131536T1 (de) *	1988-08-01	1995-12-15	Fujisawa Pharmaceutical Co	Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung
DK0427680T3 (da) *	1989-11-09	1995-12-18	Sandoz Ltd	Heteroatom-holdige cykliske forbindelser
EP0480623A1 (de) *	1990-10-11	1992-04-15	Merck & Co. Inc.	Halomakrolide und Derivate mit immunosuppressiver Wirkung
ES2179823T3 (es)	1991-09-05	2003-02-01	Abbott Lab	Inmunosupresor macrolido.
ES2102642T3 (es) *	1992-03-02	1997-08-01	Pfizer	Derivados azucares de macrolidos.
US5359060A (en)	1993-07-06	1994-10-25	Pfizer, Inc.	Phosponated derivatives of macrolides
UA41884C2 (uk) *	1993-11-05	2001-10-15	Амерікан Хоум Продактс Корпорейшн	Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
GB9618952D0 (en)	1996-09-11	1996-10-23	Sandoz Ltd	Process
GB9713730D0 (en) *	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
ME00189B (me) *	1998-03-26	2011-02-10	Astellas Pharma Inc	Preparati sa neprekidnim oslobađanjem
GB9904930D0 (en) *	1999-03-04	1999-04-28	Glaxo Group Ltd	Thiazoloindolinone compounds
JP3750527B2 (ja)	1999-05-25	2006-03-01	アステラス製薬株式会社	類似有機化合物を分離する方法
TW553946B (en)	1999-09-08	2003-09-21	Fujisawa Pharmaceutical Co	Method for separating lactone-containing high-molecular weight compounds
ES2177373B1 (es) *	1999-11-26	2003-11-01	Astur Pharma Sa	Preparacion de azitromicina en su forma no cristalina
GB0012383D0 (en)	2000-05-22	2000-07-12	Novartis Ag	Organic compounds
PL372247A1 (en)	2002-02-01	2005-07-11	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BR0307515A (pt)	2002-02-01	2004-12-07	Pfizer Prod Inc	Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
MXPA04007847A (es) *	2002-02-13	2005-02-24	Biogal Gyogyszergyar	Metodo para extraer un macrolido de biomateria.
JP4298212B2 (ja) *	2002-03-29	2009-07-15	大日本印刷株式会社	塩酸エピナスチン高融点型結晶の製造法
WO2004089958A2 (en) *	2003-03-31	2004-10-21	TEVA Gyógyszergyár Részvénytársaság	Crystallization and purification of macrolides
PL1558622T3 (pl) *	2003-07-24	2008-06-30	Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag	Sposób oczyszczania makrolidów
AU2003269473A1 (en)	2003-08-26	2005-03-10	Biocon Limited	A process for the recovery of substantially pure tricyclic macrolide
CA2560984A1 (en) *	2004-06-01	2005-12-15	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Process for preparation of amorphous form of a drug
JP2008512125A (ja) *	2004-09-10	2008-04-24	アイバックスファーマシューティカルズスポレツノストエスルチェニムオメゼニム	マクロリド化合物を単離する方法
US20080312447A1 (en)	2004-09-10	2008-12-18	Ivax Pharmaceuticals S.R.O.	Process for Isolation of Crystalline Tacrolimus
GT200500282A (es) *	2004-10-12	2006-05-04		Heteroatomos conteniendo compuestos triciclicos.
CA2584430A1 (en) *	2004-12-01	2006-06-08	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Methods for preparing pimecrolimus

2005
- 2005-12-01 CA CA002584430A patent/CA2584430A1/en not_active Abandoned
- 2005-12-01 US US11/293,353 patent/US7279571B2/en not_active Expired - Fee Related
- 2005-12-01 KR KR1020077010037A patent/KR20070060144A/ko not_active Ceased
- 2005-12-01 TW TW094142326A patent/TW200628483A/zh unknown
- 2005-12-01 CA CA002584365A patent/CA2584365A1/en not_active Abandoned
- 2005-12-01 US US11/293,286 patent/US7439252B2/en not_active Expired - Fee Related
- 2005-12-01 TW TW094142290A patent/TWI315310B/zh not_active IP Right Cessation
- 2005-12-01 WO PCT/US2005/043542 patent/WO2006060615A1/en not_active Ceased
- 2005-12-01 MX MX2007005222A patent/MX2007005222A/es unknown
- 2005-12-01 EP EP05848723A patent/EP1817317B1/de not_active Expired - Lifetime
- 2005-12-01 WO PCT/US2005/043544 patent/WO2006060617A1/en not_active Ceased
- 2005-12-01 JP JP2006551652A patent/JP2007519757A/ja active Pending
- 2005-12-01 US US11/293,283 patent/US7589100B2/en not_active Expired - Fee Related
- 2005-12-01 CA CA002584360A patent/CA2584360A1/en not_active Abandoned
- 2005-12-01 WO PCT/US2005/043541 patent/WO2006060614A1/en not_active Ceased
- 2005-12-01 EP EP05848573A patent/EP1817315A1/de not_active Withdrawn
- 2005-12-01 EP EP05848588A patent/EP1817316A1/de not_active Withdrawn
- 2005-12-01 JP JP2006551655A patent/JP2007523896A/ja active Pending
- 2005-12-01 CA CA002584358A patent/CA2584358A1/en not_active Abandoned
- 2005-12-01 AT AT05848723T patent/ATE469908T1/de not_active IP Right Cessation
- 2005-12-01 JP JP2006551654A patent/JP2007519758A/ja active Pending
- 2005-12-01 US US11/293,747 patent/US7645876B2/en not_active Expired - Fee Related
- 2005-12-01 WO PCT/US2005/043543 patent/WO2006060616A1/en not_active Ceased
- 2005-12-01 EP EP05826343A patent/EP1817314A1/de not_active Withdrawn
- 2005-12-01 JP JP2006551653A patent/JP2007523069A/ja active Pending
- 2005-12-01 DE DE602005021684T patent/DE602005021684D1/de not_active Expired - Lifetime
- 2005-12-01 MX MX2007005221A patent/MX2007005221A/es unknown
- 2005-12-01 TW TW094142291A patent/TW200631955A/zh unknown
2007
- 2007-04-30 IL IL182871A patent/IL182871A0/en unknown
- 2007-04-30 IL IL182869A patent/IL182869A0/en unknown
- 2007-04-30 IL IL182872A patent/IL182872A0/en unknown
- 2007-04-30 IL IL182870A patent/IL182870A0/en unknown
- 2007-07-24 US US11/881,033 patent/US20070270451A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2007005222A (es)	2007-06-26
US7589100B2 (en)	2009-09-15
EP1817316A1 (de)	2007-08-15
WO2006060617A1 (en)	2006-06-08
EP1817317B1 (de)	2010-06-02
EP1817314A1 (de)	2007-08-15
US20060142564A1 (en)	2006-06-29
US20060147540A1 (en)	2006-07-06
KR20070060144A (ko)	2007-06-12
EP1817315A1 (de)	2007-08-15
WO2006060614A9 (en)	2006-08-31
US20070270451A1 (en)	2007-11-22
MX2007005221A (es)	2007-06-22
JP2007523069A (ja)	2007-08-16
JP2007523896A (ja)	2007-08-23
WO2006060616A1 (en)	2006-06-08
TW200628483A (en)	2006-08-16
CA2584430A1 (en)	2006-06-08
CA2584365A1 (en)	2006-06-08
EP1817317A1 (de)	2007-08-15
TWI315310B (en)	2009-10-01
IL182871A0 (en)	2007-08-19
US7279571B2 (en)	2007-10-09
JP2007519757A (ja)	2007-07-19
CA2584360A1 (en)	2006-06-08
DE602005021684D1 (de)	2010-07-15
IL182869A0 (en)	2007-08-19
US20060155119A1 (en)	2006-07-13
IL182870A0 (en)	2007-08-19
US20060135548A1 (en)	2006-06-22
US7439252B2 (en)	2008-10-21
TW200626604A (en)	2006-08-01
CA2584358A1 (en)	2006-06-08
US7645876B2 (en)	2010-01-12
TW200631955A (en)	2006-09-16
WO2006060614A1 (en)	2006-06-08
JP2007519758A (ja)	2007-07-19
IL182872A0 (en)	2007-08-19
WO2006060615A1 (en)	2006-06-08

Legal Events

Date	Code	Title	Description
2010-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE469908T1 (de)	2010-06-15	Verfahren zur herstellung von pimecrolimus
ATE510838T1 (de)	2011-06-15	Verfahren zur herstellung von 2-methyl-1-(2- methylpropyl)-1h-imidazoä4,5-cüä1,5ünaphthyridi - 4-amin
DE502006000218D1 (de)	2008-01-24	Verfahren zur Herstellung von SiOC-verknüpften, linearen Polydialkylsiloxan-Polyoxyalkylen-Blockcopolymeren
DE60333149D1 (de)	2010-08-12	Verfahren zur Herstellung von organischen elektrolumineszenten Vorrichtungen
ATE435209T1 (de)	2009-07-15	Verfahren zur herstellung von montelukast-natrium
ATE440888T1 (de)	2009-09-15	Verfahren zur herstellung von glatiramer
ATE408609T1 (de)	2008-10-15	Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
ATE529409T1 (de)	2011-11-15	Verfahren zur herstellung von kristallinen aripiprazolformen
DE602005026987D1 (de)	2011-04-28	Verfahren zur herstellung von 1,2-dichlorethan
ATE482966T1 (de)	2010-10-15	Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE529395T1 (de)	2011-11-15	Verfahren zur herstellung von organischen carbonaten
ATE453603T1 (de)	2010-01-15	Integriertes verfahren zur selektiven oxydation von organischen verbindungen
ATE546524T1 (de)	2012-03-15	Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür
ATE527012T1 (de)	2011-10-15	Verfahren zur herstellung von medizinprodukten mit einer opferstruktur
ATE486841T1 (de)	2010-11-15	Verfahren zur herstellung von pregabalin und salzen daraus
ATE516290T1 (de)	2011-07-15	Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
ATE455778T1 (de)	2010-02-15	Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
DE502006006803D1 (de)	2010-06-02	Verfahren zur herstellung von leder
EP1848843A4 (de)	2011-09-28	Verfahren zur herstellung von gerichtet erstarrten verfestigten siliciumstäben
ATE376997T1 (de)	2007-11-15	Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
ATE402684T1 (de)	2008-08-15	Elastische befestigungslasche, befestigungssystem und verfahren zur herstellung davon
DE602005016095D1 (de)	2009-10-01	Verfahren zur herstellung von hochreinem teicoplanin
ATE466843T1 (de)	2010-05-15	Verfahren zur herstellung von n-piperidino-1,5- diphenylpyrazol-3-carboxamid-derivaten
DE602004014264D1 (de)	2008-07-17	Verfahren zur herstellung von olanzapin
ATE459610T1 (de)	2010-03-15	Verfahren zur herstellung von alkenylbernsteinsäureanhydriden